Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 4/20 | 1.00 |
| ▸ | BCHE | P06276 | 1/20 | 1.00 |
| ▸ | ACHE | P22303 | 1/20 | 1.00 |
| ▸ | NPC1 | O15118 | 1/20 | 0.75 |
| ▸ | RAB9A | P51151 | 1/20 | 0.75 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.72 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.72 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.72 |
| ▸ | MAPT | P10636 | 1/20 | 0.72 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.72 |
| ▸ | GAA | P10253 | 1/20 | 0.70 |
| ▸ | ATM | Q13315 | 1/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL373197 | 1.00 | CHRNA7 (1.00) | CHRNA7BCHEACHENPC1RAB9A | |
| SCHEMBL372949 | 1.00 | CHRNA7 (1.00) | CHRNA7BCHEACHENPC1RAB9A | |
| SCHEMBL372913 | 0.93 | CHRNA7 (0.86) | CHRNA7BCHEACHENPC1RAB9A | |
| SCHEMBL13595715 | 0.88 | CHRNA7 (0.79) | CHRNA7BCHEACHENPC1RAB9A | |
| SCHEMBL373320 | 0.88 | CHRNA7 (0.79) | CHRNA7BCHEACHENPC1RAB9A | |
| SCHEMBL373371 | 0.86 | CHRNA7 (0.76) | CHRNA7BCHEACHENPC1RAB9A | |
| SCHEMBL7367520 | 0.86 | CHRNA7 (0.76) | CHRNA7BCHEACHENPC1RAB9A | |
| SCHEMBL373759 | 0.86 | CHRNA7 (0.75) | CHRNA7BCHEACHENPC1RAB9A | |
| SCHEMBL7358272 | 0.86 | NPC1 (1.00) | CHRNA7BCHEACHENPC1RAB9A | |
| SCHEMBL373044 | 0.86 | CHRNA7 (1.00) | CHRNA7BCHEACHENPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 83 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060160835-A1 | Methods and compositions for treatment of central nervous system disorders | BENCHERIF MEROUANE | 2006-07-20 | — | — | US | claimed |
| US-7067261-B2 | Methods and compositions for treatment of central nervous system disorders | TARGACEPT, INC. (US) | 2006-06-27 | — | — | US | claimed |
| EP-0885221-B1 | AZABICYCLIC ESTERS OF CARBAMIC ACIDS USEFUL IN THERAPY | ASTRAZENECA AB (SE) | 2002-06-12 | — | — | EP | claimed |
| US-5998429-A | Azabicyclic esters of carbamic acids useful in therapy | ASTRA AB (SE) | 1999-12-07 | — | — | US | claimed |
| EP-0885221-A1 | AZABICYCLIC ESTERS OF CARBAMIC ACIDS USEFUL IN THERAPY | Astra Aktiebolag (SE) | 1998-12-23 | — | — | EP | claimed |
| WO-1997030998-A1 | AZABICYCLIC ESTERS OF CARBAMIC ACIDS USEFUL IN THERAPY | ASTRA AKTIEBOLAG (SE) | 1997-08-28 | — | — | WO | claimed |
| US-20140234270-A1 | TREATMENT WTH ALPHAT SELECTIVE LIGANDS | TARGACEPT, INC. (US) | 2014-08-21 | — | — | US | disclosed |
| US-8541447-B2 | 3-substituted-2-(arlyalkyl)-1-azabicycloalkanes and methods of use thereof | TARGACEPT, INC. (US) | 2013-09-24 | — | — | US | disclosed |
| US-8541447-B2 | 3-substituted-2-(arlyalkyl)-1-azabicycloalkanes and methods of use thereof | TARGACEPT, INC. (US) | 2013-09-24 | — | — | US | disclosed |
| EP-2484363-A1 | (2S,3R)-N-(2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-5-methylthiophene-2-carboxamide | Targacept, Inc. (US) | 2012-08-08 | — | — | EP | disclosed |
| US-20120136024-A1 | 3-Substituted-2-(arlyalkyl)-1-azabicycloalkanes and Methods of Use Thereof | TARGACEPT, INC. (US) | 2012-05-31 | — | — | US | disclosed |
| US-20120136024-A1 | 3-Substituted-2-(arlyalkyl)-1-azabicycloalkanes and Methods of Use Thereof | TARGACEPT, INC. (US) | 2012-05-31 | — | — | US | disclosed |
| US-8158649-B2 | 3-substituted-2(arylalkyl)-1-azabicycloalkanes and methods of use thereof | TARGACEPT, INC. (US) | 2012-04-17 | — | — | US | disclosed |
| US-6110914-A | Spiroazabicyclic heterocyclic compounds | ASTRA AKTIEBOLAG (SE) | 2000-08-29 | — | — | US | disclosed |
| EP-0996622-A1 | NOVEL SPIROAZABICYCLIC HETEROCYCLIC COMPOUNDS | Astra Aktiebolag (SE) | 2000-05-03 | — | — | EP | disclosed |
| US-6054464-A | Azabicyclic esters of carbamic acids useful in therapy | ASTRA AKTIEBOLAG (SE) | 2000-04-25 | — | — | US | disclosed |
| US-5998429-A | Azabicyclic esters of carbamic acids useful in therapy | ASTRA AB (SE) | 1999-12-07 | — | — | US | disclosed |
| WO-1999003859-A1 | NOVEL SPIROAZABICYCLIC HETEROCYCLIC COMPOUNDS | ASTRA AKTIEBOLAG (SE) | 1999-01-28 | — | — | WO | disclosed |
| EP-0885221-A1 | AZABICYCLIC ESTERS OF CARBAMIC ACIDS USEFUL IN THERAPY | Astra Aktiebolag (SE) | 1998-12-23 | — | — | EP | disclosed |
| WO-1997030998-A1 | AZABICYCLIC ESTERS OF CARBAMIC ACIDS USEFUL IN THERAPY | ASTRA AKTIEBOLAG (SE) | 1997-08-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060160835-A1 | Methods and compositions for treatment of central nervous system disorders | JAK2, ERBB2, ERBB3 | CHRNA7 46/4885BCHE 976/4885ACHE 279/4885 |
| US-20140234270-A1 | TREATMENT WTH ALPHAT SELECTIVE LIGANDS | CHRNA7, CHRNA2, CHRNA4 | CHRNA7 1/4885BCHE 59/4885ACHE 109/4885 |
| US-20120136024-A1 | 3-Substituted-2-(arlyalkyl)-1-azabicycloalkanes and Methods of Use Thereof | CHRNA7, CHRNA1, CHRNA3 | CHRNA7 1/4885BCHE 112/4885ACHE 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.